Idiopathic achalasia
ORPHA:930DiseaseAutosomal recessive, Not applicableAll ages
Ассоциированные гены4
| Ген | Полное название | Тип связи | Тип гена | OMIM |
|---|---|---|---|---|
| CRLF1 | cytokine receptor like factor 1 | Disease-causing germline mutation(s) in | gene with protein product | 604237 |
| HLA-DQA1 | major histocompatibility complex, class II, DQ alpha 1 | Major susceptibility factor in | gene with protein product | 146880 |
| HLA-DQB1 | major histocompatibility complex, class II, DQ beta 1 | Major susceptibility factor in | gene with protein product | 604305 |
| NOS1 | nitric oxide synthase 1 | Disease-causing germline mutation(s) in | gene with protein product | 163731 |
Фенотипы (HPO)10
Очень частый (80–99%)1
HP:0002015Dysphagia
Частый (30–79%)5
HP:0001824Weight loss
HP:0002020Gastroesophageal reflux
HP:0012387Bronchitis
HP:0012735Cough
HP:0100749Chest pain
Периодический (5–29%)4
HP:0002100Recurrent aspiration pneumonia
HP:0004395Malnutrition
HP:0030828Wheezing
HP:0031085Decreased prealbumin level
Эпидемиология13
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-9 / 1 000 000 | — | Europe | Class only |
| Point prevalence | 1-9 / 100 000 | 8 | Worldwide | Value and class |
| Point prevalence | 1-5 / 10 000 | 10.82 | Canada | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.29 | Korea, Republic of | Value and class |
| Point prevalence | 1-5 / 10 000 | 13.5 | Ireland | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.7 | Iceland | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.8 | Singapore | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.59 | Italy | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.73 | Iceland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.3 | Singapore | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.39 | Korea, Republic of | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.63 | Canada | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.77 | Worldwide | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)